Google Alert - pharmaceutical news

News 6 new results for pharmaceutical news

Osaka-based pharmaceutical firm to launch clinical trial on anti-cancer drug ... Shanghai Daily (subscription) The pharmaceutical company plans to submit clinical trial applications to the Ministry of Health, Labour and Welfare within months to further develop treatments for cancer patients, said the country's public broadcaster Nippon Hoso Kyokai (NHK). See all stories on this topic »

Taro Pharmaceutical Industries Ltd. (TARO): Will This Pharma Takeover Go ... Insider Monkey (blog) Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced in November a further delay on a vote by minority holders of the sale of the remaining minority interest to Sun Pharmaceutical Industries (SUNP - NSE). The minority holders have held out for a ... See all stories on this topic » Insider Monkey (blog)

Research and Markets: South and Central American Pharmaceutical Directory ... PharmiWeb.com (press release) The new edition of the South & Central American Pharmaceutical Directory has been thoroughly researched, to bring you a completely up-to-date guide to the Latin American ever-changing pharmaceutical industry. If you need to source from, or sell to ... See all stories on this topic »

Prospect for Nigeria's pharmaceutical industry BusinessDay The health needs of a nation reflect on certain essential medicines consumed by the populace. With the determining factor in the pharmaceutical business dependent on increasing disease pattern, over-the-counter (OTC) medicines such as analgesics, ... See all stories on this topic » BusinessDay

Watson Pharmaceuticals, Inc. Is Now Actavis, Inc. Daily Markets (press release) PARSIPPANY, N.J., Jan. 24, 2013 /PRNewswire/ – Watson Pharmaceuticals, Inc. today announced that the company has adopted Actavis, Inc. (ACT) as its new global name and will today begin trading under a new symbol — ACT — on the New York Stock ... See all stories on this topic »

Allergan to acquire MAP Pharmaceuticals in $958 million deal The Pharma Letter US drugmaker Allergan (NYSE: AGN) has entered into a definitive merger agreement to acquire 100% of the shares of fellow USA-based MAP Pharmaceuticals (Nasdaq: MAPP) for a price of $25.00 per share, a 60% premium over MAP's closing stock price ... See all stories on this topic »

---

Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.

Delete this alert.
Create another alert.
Manage your alerts.